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Background: Several guidelines for cystic fibrosis (CF) caregivers exist, but information about their implementation is lacking.
Methods: Adherence to European Consensus Guidelines for CF was studied by sending surveys to named healthcare professionals in 487 CF
centres/units. Data were analysed qualitatively.
Results: Data were obtained from 177 CF clinics, providing care for 21,177 patients (33% response rate). Access to specialist healthcare
professionals was good according to 80% of respondents, although only 59% reported access to specialist pharmacists. Of the respondents, 16%
reported unlimited access to inpatient CF beds, however 22% reported a lack of availability of immediate care. Most respondents (84%) reviewed
their patients quarterly as outpatients. Shared-care models were used by 84% of respondents. Availability and adequacy of funding presented an
issue for many, although 8% of respondents indicated that key funding was derived from CF charities.
Conclusions: The respondents demonstrated a high degree of implementation of European Consensus Guidelines. However, areas for
improvement include shared care, access to care and funding inequalities.
© 2009 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Cystic fibrosis; Shared care; Inpatient care; Outpatient care; Survey; European1. Introduction
The prognosis for patients with cystic fibrosis (CF) has im-
proved considerably over the last three to four decades [1,2].
Survival age now exceeds 30 years in some populations [2],
compared with only 20 years in the 1970s [3]. As most people
diagnosed with CF now live into adulthood, it can no longer be
considered a fatal disease of childhood. Indeed, inmost developed
countries, most CF-related deaths occur in adulthood. To deliver
high standards of care, both in terms of people and facilities, the
costs for an individual personwith CF are lifelong and high. Costs
are primarily attributable to hospitalisations, home-based care and
use of medication, especially oral, nebulised and intravenous⁎ Corresponding author. Belfast City Hospital, Ground Floor, Lisburn Road,
Belfast, BT9 7AB, UK. Tel.: +353 028 9026 3683; fax: +353 028 9026 3546.
E-mail address: stuart.elborn@bch.n-i.nhs.uk (J.S. Elborn).
1569-1993/$ - see front matter © 2009 Published by Elsevier B.V. on behalf of Eu
doi:10.1016/j.jcf.2009.05.004antibiotics as a consequence of treatingPseudomonas aeruginosa
infections [4–6], and rhDNase [7].
The complexity of CF requires a holistic approach to treat-
ment, providing medical care and support for patients and their
families or carers. Previous studies have shown that care from
dedicated teams in specialist CF centres is the best approach and is
associatedwith improved survival and quality of life [8–10]. Such
care requires early treatment interventions, and frequent clinical
evaluations and monitoring for complications by physicians and
other healthcare workers specifically trained in the management
of CF.
Several guidelines have been written to assist CF caregivers
in the evaluation and monitoring of patients; however, there is a
lack of uniformity in many of the agreed recommendations from
Europe and the USA [11,12]. Recent European Cystic Fibrosis
Society (ECFS) Consensus Guidelines [13] defined appropriate
standards of care and aimed to bring uniformity across Europe.
These guidelines recommend that: patients have access toropean Cystic Fibrosis Society.
Table 1
Distribution and responses among surveyed cystic fibrosis clinics.
Country Number of
surveys sent
Number of
responses received
Number of patients
represented
Austria 8 3 306
Belgium 13 6 617
Bulgaria 4 0 NA
Czech Republic 10 4 589
Denmark 2 2 526
England 47 24 4056
Estonia 2 0 NA
Finland 2 1 NA
France 55 18 2163
Germany 151 41 3189
Greece 4 1 75
Hungary 10 7 374
Iceland 1 1 9
Ireland (Northern and
Republic)
24 7 996
Israel 7 3 280
Italy 47 13 3156
Lithuania 1 1 60
Macedonia 3 0 NA
The Netherlands 17 8 1455
Norway 5 1 12
Poland 13 5 698
Portugal 11 4 216
Slovakia 1 0 NA
Russian Federation 11 1 58
Scotland 10 4 324
Spain 67 9 912
Sweden 4 3 425
Switzerland 9 8 491
Turkey 1 1 150
Ukraine 1 0 NA
Wales 3 1 40
NA = not available.
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should offer inpatient care when needed; a clear infection-
control policy should be provided and implemented within
centres; a structured and regular outpatient care programme
should exist; and the option for shared care should be offered
when appropriate.
Shared care recognises that some families and patients can-
not travel long distances to a specialist centre for routine care.
The ECFS Consensus Guidelines indicate that agreed models of
shared care are needed, but must not lead to suboptimal care for
patients. One approach is for satellite or networked CF centres
to work closely with specialist CF centres. They should have, as
a minimum, dedicated funded time from a senior paediatrician
or physician, a dietician, a physiotherapist and a nurse with a
special interest in CF. Similar to specialist centres, satellite CF
centres should run dedicated CF clinics equivalent in standard
to those within specialist centres [13].
Assessment of CF centres provides important insights into
current management of European CF patients and provides
comparative data across Europe. This report presents the results
of a pan-European survey of CF centres. The objective of the
survey was to investigate current patterns of CF care across
Europe and to compare the data with recommendations from the
ECFS Consensus guidelines. The survey investigated two main
areas: provision of care (presented here) and infection control
(presented in a companion paper [14]).
2. Methods
A survey to assess the extent to which the new guidelines were
being followed throughout Europe was developed and distributed
to CF centres in 2005 and 2006. Clinics and individuals were
selected qualitatively in several ways. Participants who were
members of the ECFS were identified using mailing lists from
the Society. Additional centres and participants were identified
through peer networks. In total, 544 surveys were sent to named
healthcare professionals across 487 units and CF clinics: in more
than 85% of cases, only one specialist within a unit received a
questionnaire. In order to ensure both adult and paediatric services
were included, multiple clinics within single centres may have
received a questionnaire: in 33 units, two specialists received a
questionnaire; and in four units, three or more specialists received
a questionnaire. The questionnaire included both open and di-
rected questions (see Appendix). The survey was designed to
evaluate:
• awareness and/or implementation of the existing standards of
care document or implementation of country-specific clinical
guidelines
• healthcare teams— whether specialists were available to the
centre and whether the structure was in line with current
guidelines
• inpatient care — bed provision, ongoing monitoring and
testing
• outpatient care and shared care — what provisions were in
place
• source and adequacy of funding• treatment of infection and infection-control policies
(reported elsewhere [14]).
All surveys were analysed manually and, since the survey
was qualitative, statistical analyses were not undertaken. Data
were analysed as the percentage of responders answering each
question. Because of the anonymous nature of the question-
naire, it was not possible to exclude multiple sets of data
received from one centre; however, as each set of data related to
a separate clinic within a centre, duplication of data was limited.
Data are presented as number of respondents/total number of
responses.
3. Results
3.1. Geographic spread of respondents
A total of 177 completed surveys were returned, representing
a response rate of 33% and providing data from clinics caring
for a total of 21,177 patients. Centres from 27 countries
responded to the survey, representing 84% of the 32 countries
sampled and providing a summary of care standards across
Europe (Table 1). England, France, Germany and Italy provided
Fig. 1. Number of patients in treatment clinics.
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were received from Eastern European countries (12% of all
responses), which provided data on clinics caring for a total of
1929 patients (Table 1). Just over half (56%) of all respondents
were members of the ECFS. Most respondents reported that
they had either read the current standards of care document
(75%, n=133/177) or were aware of it (87%, n=154/177).
Most respondents (68%, n=120/177) also said that, at the time
of response, their country had clinical guidelines for the
management of patients with CF.
3.2. Analysis of CF centres: healthcare teams and resources
Of the 177 respondents, 46% (n=82/177) operated in clinics
that treated both children and adults; specialist adult clinics
represented 23% (n=40/177) of respondents and paediatric
clinics 31% (n=55/177) of respondents. Of the responding
clinics, a large number (31%, n=55/177) cared for between 101
and 200 CF patients, 29% (n=52/177) cared for 51–100
patients and 24% (n=42/177) cared for 0–50 patients (Fig. 1).
Most units had specialist staff available for patients with
CF, whether they were treated as inpatients or outpatients. AsFig. 2. Number of specialist irecommended in the ECFS Consensus Guidelines, 42% (n=74/
177) of respondents indicated that specialist support for CF
patients was available from each of the following: nurses,
physiotherapists, dietitians or nutritionists and psychologists.
Any four of these professionals were available in a further 25%
(n=44/177) of clinics. Almost 80% of respondents also had
access to specialist microbiologists and social workers (79%,
n=140/177 and 80%, n=142/177, respectively). However,
proportionally fewer respondents had access to specialist
clinical pharmacists (59%, n=104/177).
Specialised imaging to aid diagnosis and management of
patients with CF was available to the majority of clinics. Ultra-
sound imaging (99%, n=175/177), bronchial artery embolisation
(63%, n=112/177), computerised tomography (97%, n=172/
177) and dual-energy X-ray absorptiometry (74%, n=131/177)
were the most commonly available imaging services. Bronchial
artery embolisation was available at 63% (n=112/177) of
responding clinics based in Western Europe compared with
28% (n=50/177) of responding clinics in Eastern Europe. With
this one exception, there were no notable variations in imaging, or
indeed other clinical services provided, with respect to the
geographical location of the responding clinics.npatient beds per centre.
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The majority (54%, n=96/177) of centres had between 0 and
10 specialists beds available for CF inpatients (Fig. 2). Not all
clinics had specialist beds available, with 10% n=18/177)
admitting patients to other wards e.g. pulmonary or respiratory
wards. For most patients with CF access to an inpatient bed was
immediate if needed (78%, n=138/177), but 22% (n=39/177)
of patients still had to wait for admission to a bed for treatment
throughout Europe. With respect to patient care and complica-
tions, 69% (n=122/177) of clinics worked within written
guidelines for complications. Most of the clinics surveyed had
written infection-control policies in place (77%, n=136/177).
Most commonly, clinics had between zero and ten beds
available in their hospital exclusively for CF patients (55%,
n=97/177). The majority (62%, n=110/177) of clinics had
single rooms available in their hospital for CF patients.
3.4. Access to care: outpatients
Only 8% (n=14/177) of respondents indicated that patients
were seen as outpatients on a monthly basis, with the majority
(84%, n=149/177) ensuring patients were evaluated at least once
every 3 months. However, 8% (n=14/177) saw their patients less
than every 3months.More than 75% (n=133/177) of respondents
indicated that, in line with the ECFS Consensus Guidelines,
patients at outpatient clinics routinely underwent assessment by a
CF physician and a nurse (94%, n=166/177), which included:
physical examination (99%, n=175/177), including weight for all
patients (98%, n=173/177) and height for young children (75%,
n=133/177); respiratory testing comprising pulmonary tests
(98%, n=173/177), cough or sputum swabs (98%, n=173/177)
as well as routine oximetry (88%, n=156/177); discussion with a
dietitian and a physiotherapist (92%, n=162/177); and a review
of medication (99%, n=175/177) (Fig. 3).Fig. 3. Routine monitoring activities of3.5. Shared care
Overall, 84% (n=148/177) of respondents indicated that
they operated a shared-care model. When further analysed, it
was clear that for many of these clinics (34%, n=51/148) this
was offered to their entire CF population. However, nearly half
of the responding clinics (46%, n=68/148) had a minority of
patients within the shared-care model.
3.6. Funding
For all respondents, the predominant funding provider of
CF services was a national healthcare system (54%) followed
by healthcare insurance (33%). A further 16% (n=29/177) of
respondents outlined that funding was a combination of national
healthcare systems and insurance. The role of CF charities
across Europe cannot be underestimated: nearly 8% (n=14/177)
of respondents highlighted this route as a key funder of services.
Approximately half of all respondents said funding was
guaranteed by the provider of medical care (54%, n=96/177),
but for the remaining half, funding was either guaranteed but
inadequate (38%, n=67/177), or was not guaranteed in any way
(5%, n=9/177).
4. Discussion
This survey provides insight into current practice in CF
management and patient access to treatment throughout Europe.
Although it is difficult to determine the total number of people
with CF in Europe, a demographic survey undertaken in Europe
by Eurocare-CF estimates this number at approximately 30,000
[15]. Thus, this survey reflects the care provided for around
70% of CF patients in Europe. It is encouraging to find that
European Guidelines laid down by the Consensus panel [13]
are being followed to a high degree. High standards of carefered at outpatient clinics (n=94).
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with CF further into adulthood, and the large proportion of
dedicated adult care clinics is indicative of this.
It is evident that multidisciplinary teams are available in most
CF clinics. However, only 59% of clinics reported access to
a clinical pharmacist. Since CF treatment involves complex
polypharmacy this is an important deficit, and continues to be
an unmet need in CF care. Clinical pharmacists provide valuable
advice on drug interactions and administration (inhaled, intra-
venous and oral drugs), thus offering valuable knowledge to
optimise treatment. In addition, they provide an important inter-
face with the patient and/or carer to ensure the success of and
adherence to prescribed multidrug treatments.
Access to care was reasonable in most clinics, with patients
being evaluated at least every 3 months. This indicates that
most clinics followed the broader recommendation from the
ECFS Consensus Guidelines (which suggests that patients are
seen every 1–3 months), whereas fewer patients were
examined every month (in line with the preferred assessment
timeline) [13]. A further aspect of care services, shared care, is
an integral part of the ECFS Consensus Guidelines and is
particularly important for children. The sharing of care
between the CF clinic and staff at the local hospital provides
valuable support to patients or families who will not or cannot
travel long distances. Responses from this survey indicated that
approximately half of responding clinics (84%) provided
shared care for some or most of their patients. While the
provision of shared care is valuable to some patients, the need
to maintain the quality of such care is paramount. This issue is
addressed in the ECFS Consensus Guidelines, which state that
this type of model needs to be well thought through and must
not result in suboptimal care.
Notable differences exist in funding systems for CF centres
across Europe: for example, Denmark has no funding limita-
tions impacting on patient CF management, while in the UK a
funding band system according to grade of disease severity is
under consideration, and in Germany funding is largely through
insurance and local support groups [13]. The current survey
highlights the different levels and types of funding available
across Europe. While half of centres had guaranteed adequate
funding, a further 43% had guaranteed but inadequate, or
unguaranteed funding. Further work is required to assess
whether there are measurable impacts of different funding
arrangements on patient care and/or outcomes.
A potential limitation of the study is reflected in the response
rate of under 50%. It is possible that clinics that did not closely
follow ECFS Consensus guidelines did not return question-
naires, or that responding clinics reported ‘best case’ scenarios
rather than the day-to-day position. Thus, the results may over-
estimate adherence to guidelines and standards of care across
Europe. In addition, the results suggest around 70% of the pre-
sumed patient population are being cared for in only 24% of
European centres. This would suggest that there are many
clinics, not captured in the survey results, each treating a small
number of patients. Further research would be required to
ascertain whether clinics with smaller populations implement
European guidelines in a similar way to larger clinics. A secondpossible limitation lies in the distribution of responding clinics.
While the study provides information on shared care across
Europe, a bias was seen in the distribution of clinics that
returned questionnaires. Four countries provided responses
from more than 10 clinics (England, France, Germany, Italy),
and overall, were responsible for the majority of returned
questionnaires. Only 12% of questionnaires were received from
Eastern European countries. The results, therefore, may be
biased towards practice in Western Europe and be less
representative of that in Eastern Europe.
Further data would be needed to provide a more substantial
data set from which to extrapolate these interesting observations
to determine what changes in infrastructure and/or behaviour
are required to ensure adherence to established guidance
documents. Furthermore, since survival rates have increased,
it would be of interest to broaden the scope of such a survey to
examine the impact of adherence and non-adherence on clinical
and health economic outcomes.Funding
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approved the version that is included here.Appendix A. European Cystic Fibrosis Society (ECFS)
standards of care survey
Toward optimal service provision for patients with cystic
fibrosis (CF)• Please answer every question
• Centres will be anonymous and will not be identified in any
subsequent report
• The data from this survey will be presented at the Chiron
Biopharmaceuticals symposium at ECFS on Thursday 23
June 2005, 19:00–20:30 h, Room Zeus, Conference Centre,
Crete, Greece
• Deadline for completion of surveyWednesday 27th April 2005
• Please complete the survey online. The web address is http://
www.windrush.net/ecfs/survey.htm
• Alternatively, you can fax the completed forms to the survey
secretariat using the fax-back sheet at the end of this document.
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